Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P602: CD-TREAT a novel dietary therapy of active Crohn’s disease using the exclusive enteral nutrition paradigm

ECCO '19 Copenhagen

Year: 2019
Authors:

V. Svolos*1, R. Hansen2, U. Z. Ijaz3, L. Gervais2, H. Duncan2, R. Tayler2, A. Barclay2, D. Flynn2, V. Garrick2, L. Curtis2, E. Buchanan2, T. Cardigan2, D. R. Gaya4, S. Milling5, R. K. Russell2, K. Gerasimidis1

1Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK, 2Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, UK, 3School of Engineering, University of Glasgow, Glasgow, UK, 4Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, UK, 5Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

P603: Paediatric onset inflammatory bowel disease is not associated with more disability compared with adult onset disease

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Picardo*1, R. Panaccione1, G. Kaplan1,2, C. Seow1,2, J. deBruyn3, Y. Leung1,4

1Univeristy of Calgary, Inflammatory Bowel Disease Unit, Calgary, Canada, 2University of Calgary, Community Health Sciences, Calgary, Canada, 3Univeristy of Calgary, Pediatric Gastroenterology, Calgary, Canada, 4University of British Columbia, Inflammatory Bowel Disease Unit, Vancouver, Canada

P604: Biologics with or without a combination with 5-ASA in ulcerative colitis: frequency of usage and effect on the course of disease in the Swiss IBD-Cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Roth*1, P. Schreiner1, J-B. Rossel2, B. Misselwitz3, M. Scharl1, G. Rogler1, L. Biedermann1

1University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, 2University of Lausanne, Institute of Social and Preventive Medicine, Lausanne, Switzerland, 3University Hospital Bern, Department of Visceral Surgery and Medicine, Bern, Switzerland

P605: CRP reduction rate following initiation of anti-tumour necrosis factor-α induction therapy predicts secondary loss of response in patients with Crohn's disease

ECCO '19 Copenhagen

Year: 2019
Authors:

J. H. Song*1, S. N. Hong1, T. J. Kim1, E. R. Kim1, D. K. Chang1, Y-H. Kim1

1Samsung Medical Center, Department of Medicine, Seoul, South Korea

P606: Steroid use in inflammatory bowel disease patients on biological therapy in Montenegro

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Smolovic*1, M. Lukic1, O. Sekulic1, D. Muhovic1, V. Milosevic2, B. Vukcevic3

1Clinical Center of Montenegro, Podgorica, Montenegro, 2Ars Medica, Podgorica, Montenegro, 3Faculty of Medicine, University of Montenegro, Podgorica, Montenegro

P607: Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Narula1, B. Lauzon*1, J. Marshall1

1McMaster University, Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute, Hamilton, ON, Canada

P608: Crohn’s disease patients with high baseline symptoms achieve clinical remission more rapidly with Budesonide than with Mesalazine

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Kunz*1, R. Hofmann1

1Tillotts Pharma AG, Rheinfelden, Switzerland

P609: Handsewn anastomosis after ileo-colic resection for Crohn’s disease: a lost art?

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Gouvea Monteiro de Camargo1, S. Brandstetter1, A. Aiello2, L. Stocchi1, T. Hull1, I. Lavery1, J. M. Church1, S. R. Steele1, M. Valente1, S. Holubar*1

1Cleveland Clinic Foundation, Colorectal Surgery, Cleveland, USA, 2Cleveland Clinic Foundation, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, USA

P610: Penetration, short- and long-term efficacy of anti-TNF-α therapy for ulcerative colitis between 2010–2016 in Hungary

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Molnár*1, F. Nagy1, Z. Szepes1, K. Farkas1, R. Bor1, A. Bálint1, Á. Milassin1, A. Fábián1, M. Rutka1, K. Szántó1

1University of Szeged, First Department of Medicine, Szeged, Hungary

P611: A real-world assessment of golimumab effect on quality of life, healthcare resource utilisation and work productivity in patients with ulcerative colitis in Greece: interim results from the GO-LIFE study

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Mantzaris*1, A. Gatopoulou2, D. Christodoulou3, K. Katsanos3, I. Mouzas4, M. Tzouvala5, G. Paspatis6, K. Thomopoulos7, S. Michopoulos8, G. Koujlakis9, I. Pachiadakis10, K. Triantafyllou11, P. Karatzas12, D. Moschovis13, G. Theocharis7, M. Tampaki14

1Evangelismos-Ophthalmiatreion Athinon-Polykliniki Hospital, Gastroenterology, Athens, Greece, 2University Hospital of Alexandroupoli, Democritus University of Thrace, 2nd Department of Internal Medicine, Alexandroupoli, Greece, 3University Hospital of Ioannina, Gastroenterology, Ioannina, Greece, 4University of Crete, Medical School, Gastroenterology, Heraklion, Greece, 5General Hospital of Nikea and Piraeus, Agios Panteleimon – Agia Varvara., Gastroenterology, Nicea, Greece, 6Venizeleio Pananeio General Hospital of Heraklion, Gastroenterology, Heraklion, Greece, 7University Hospital of Patras, Medical School, Gastroenterology, Patras, Greece, 8Alexandra General Hospital of Athens, Gastroenterology, Athens, Greece, 9Democritus University of Thrace, Digestive System Endoscopy Unit, Alexandroupoli, Greece, 10424 Military General Hospital, Gastroenterology and Hepatology, Thessaloniki, Greece, 11Second Department of Internal Medicine - Propaedeutic, Research Institute and Diabetes Center, Department of Internal Medicine, Medical School, National and Kapodistrian University of Athens, Hepatogastroenterology Unit, Athens, Greece, 12Evangelismos Hospital, Gastroenterology, Athens, Greece, 13General Hospital of Nikea and Piraeus, Agios Panteleimon – Agia Varvara, Gastroenterology, Nicea, Greece, 14Merck Sharp and Dohme Pharmaceutical, Industrial and Commercial S.A, Athens, Greece

P612: Long-term outcomes of treatment intervention according to the severity of small bowel capsule endoscopy findings in patients with Crohn’s disease: A Japanese single-centre cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Nasuno*1, H. Tanaka1, K. Sugiyama1, M. Miyakawa1, S. Motoya1

1Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan

P613: Tacrolimus as rescue therapy for steroid-dependent/steroid refractory ulcerative colitis: experience from tertiary referral centre

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Sud*1, A. S. Puri1

1GB Pant Institute of Postgraduate Medical Education and Research, Gastroenterology, New Delhi, India

P614: The utility as a biomarker of faecal calprotectin for predicting the clinical outcome of granulocyte and monocyte adsorptive apheresis treatment in patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Ueno*1, Y. Murakami1, T. Iwama1, T. Sasaki1, T. Kunogi1, K. Takahashi1, K. Tanaka2, K. Ando1, S. Kashima1, Y. Inaba3, K. Moriichi1, H. Tanabe1, M. Taruishi3, M. Fujiya1, T. Okumura1

1Asahikawa Medical University, Department of Medicine, Asahikawa, Japan, 2Asahikawa Kosei General Hospital, Asahikawa, Japan, 3Asahikawa City Hospital, Asahikawa, Japan

P615: Rescue infliximab for acute severe colitis: a single-centre experience

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Orpen-Palmer*1, F. Clegg1,2, U. Basavaraju1, G. H. Bain1, C. N. Parnaby1, M. G. Smith1, M. H. McLean1,2, J. M. Thomson1

1Aberdeen Royal Infirmary, NHS Grampian, Aberdeen, UK, 2University of Aberdeen, Aberdeen, UK

P616: Ustekinumab for refractory paediatric Crohn’s disease: experience from two UK tertiary referral centres

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Rao*1, R. Gadhok1, L. Whitley2, N. Burgess1, P. Amon1, S. Naik1, J. Lindsay1, S. McCartney2, K. Kok1

1The Royal London Hospital, Gastroenterology, London, UK, 2University College London Hospital, Gastroenterology, London, UK

P617: Evaluation of subclinical myocardial damage in patients with inflammatory bowel disease on treatment with biologics

ECCO '19 Copenhagen

Year: 2019
Authors:

G. Costantino*1, G. Mandraffino1, S. Tomeo1, A. Sitibondo1, M. Scolaro1, C. Zito2, G. Di Bella2, S. Loddo3, W. Fries1

1AOU G. Martino – Messina, Department of Clinical and Experimental Medicine, IBD Unit, University of Messina, Messina, Italy, 2AOU G. Martino – Messina, Department of Clinical and Experimental Medicine, Cardiology Unit, University of Messina, Messina, Italy, 3AOU G. Martino - Messina, Department of Clinical and Experimental Medicine, Laboratory Medicine Unit, University of Messina, Messina, Italy

P618: Vedolizumab acute infusion reactions in inflammatory bowel disease patients: results of a multi-centre retrospective observational cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Venturin1, S. Nancey1, X. Roblin2, L. Peyrin-Biroulet3, N. Mathieu4, B. Flourié1, G. Boschetti*1

1Lyon-Sud Hospital, Gastroenterology, Pierre Bénite, France, 2CHU Saint-Etienne, Gastroenterology, Saint-Etienne, France, 3CHU Nancy, Gastroenterology, Nancy, France, 4CHU Grenoble, Gastroenterology, Grenoble, France

P619: Maintenance of efficacy following tofacitinib dose reduction in patients with ulcerative colitis in stable remission

ECCO '19 Copenhagen

Year: 2019
Authors:

D. T. Rubin1, S. Travis2, B. P. Abraham3, C. Su4, N. Lawendy4, H. Fan4, D. A. Woodworth4, A. J. Thorpe4, C. I. Nduaka4, D. Quirk4, W. Reinisch*5

1University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, IL, USA, 2University of Oxford, Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, Oxford, UK, 3Houston Methodist – Weill Cornell, Division of Gastroenterology and Hepatology, Houston, TX, USA, 4Pfizer Inc., Collegeville, PA, USA, 5Medical University of Vienna, Vienna, Austria

P620: Stapled end-to-side vs. side-to-side anastomosis after ileocecectomy for Crohn’s disease: a propensity score-matched analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Brandstetter1, M. Gouvea Monteiro de Camargo1, A. Aiello2, L. Stocchi1, J. M. Church1, T. Hull1, I. Lavery1, S. R. Steele1, S. Holubar*1, M. Valente1

1Cleveland Clinic Foundation, Colorectal Surgery, Cleveland, USA, 2Cleveland Clinic Foundation, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland, USA

P621: Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive Crohn’s disease patients: results from the EVOLVE study

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Bressler*1, G. Mantzaris2, M. Silverberg3, P. Zezos3, D. Stein4, C. Colby5, T. Lissoos6, C. Lopez6, A. Natsios7, G. Radulescu8, H. Patel9, D. Demuth10, A. Yarur11

1St. Paul's Hospital, Vancouver, Canada, 2Evangelismos Hospital, Athens, Greece, 3IBD Center, Mount Sinai Hospital, Toronto, Canada, 4Evidera, London, UK, 5Evidera, California, USA, 6Takeda USA Inc., Chicago, USA, 7Takeda SA Inc., Athens, Greece, 8Takeda Canada Inc., Toronto, Canada, 9Takeda Pharmaceuticals International, Deerfield, USA, 10Takeda International - UK Branch, London, UK, 11Medical College of Wisconsin, Milwaukee, USA